Notizie Newsletter
FDA Approval Sought for KTE-X19 in Relapsed/Refractory Mantle Cell Lymphoma
December 12, 2019 - A biologics license application has been submitted to the FDA for the investigational CAR T-cell therapy KTE-X19 as a treatment for adult patients with relapsed/refractory mantle cell lymphoma (MCL). The application is based on findings from the phase ...Leggi tutto